Clincosm LogoSign in Get a demo

Leukemia, Lymphocytic, Chronic, B-Cell

Showing NaN - NaN of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (JNJ-75348780)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Birmingham, Alabama
  • +43 more
Jan 27, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Trial in United States (JCAR017 (lisocabtagene maraleucel),

Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic
  • JCAR017 (lisocabtagene maraleucel)
  • +2 more
  • Birmingham, Alabama
  • +63 more
Nov 21, 2022

Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724

Terminated
Has Results
  • Non-Hodgkin's B-cell Lymphoma
  • +5 more
  • MT-3724 Phase 1
  • MT-3724 Phase 2
  • Tucson, Arizona
  • +40 more
Jul 18, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell Trial in Worldwide (Pirtobrutinib)

Available
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +4 more
  • Stanford, California
  • +61 more
Aug 17, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma Trial in Worldwide (BMS-986403, Fludarabine, Cyclophosphamide)

Recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma
  • Birmingham, Alabama
  • +24 more
Jul 6, 2022

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)

Active, not recruiting
Has Results
  • Lymphoma
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Gilbert, Arizona
  • +53 more
Jan 25, 2022

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (CC-122, Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • La Jolla, California
  • +23 more
Aug 20, 2021

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Houston (INVAC-1)

Terminated
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • INVAC-1
  • Houston, Texas
    MD Anderson Cancer Center
Jul 6, 2020

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in Worldwide (Part 1 (Dose

Terminated
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +4 more
  • Part 1 (Dose Escalation): Duvortuxizumab
  • Part 2 (Dose Expansion): Duvortuxizumab
  • Detroit, Michigan
  • +19 more
Dec 19, 2018